JPH04169525A - Composition having serum lipid-improving function - Google Patents

Composition having serum lipid-improving function

Info

Publication number
JPH04169525A
JPH04169525A JP2293763A JP29376390A JPH04169525A JP H04169525 A JPH04169525 A JP H04169525A JP 2293763 A JP2293763 A JP 2293763A JP 29376390 A JP29376390 A JP 29376390A JP H04169525 A JPH04169525 A JP H04169525A
Authority
JP
Japan
Prior art keywords
composition
acid
vitamin
serum lipid
fish oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2293763A
Other languages
Japanese (ja)
Inventor
Hiroshige Itakura
弘重 板倉
Osamu Nakajima
修 中島
Nobuo Ikegawa
池川 信夫
Tetsuo Ikegawa
哲郎 池川
Hiroshi Mizunuma
水沼 寛
Suehito Yamagami
山上 末人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NISSEI MARINE KOGYO KK
Original Assignee
NISSEI MARINE KOGYO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NISSEI MARINE KOGYO KK filed Critical NISSEI MARINE KOGYO KK
Priority to JP2293763A priority Critical patent/JPH04169525A/en
Publication of JPH04169525A publication Critical patent/JPH04169525A/en
Pending legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE:To provide the subject composition containing squalene, a fish oil and vitamin E as essential components capable of being ingested as a food or as a component for other foods, exhibiting a blood lipid-improving effect within a short period, and having no adverse action. CONSTITUTION:The composition contains (A) squalene, (B) a fish oil preferably containing eicosapentaenoic acid and docosahexaenoic acid in large amounts, especially >=20wt.% and >=10wt.%, respectively, and (C) vitamin E as essential components. preferably further (D) soybean lecithin and (E) a vegetable oil preferably containing linoleic acid and gamma-linolenic acid in large amounts, especially >=50wt.% and >=7wt.%, respectively, preferably in a ratio comprising A=30-85wt.%, B, D, E=5-50wt.%, respectively, and C=0.1-10wt.%. The composition has a thrombogenesis-preventing action and a thrombosis-treating activity which are useful for preventing and treating cerebral thrombosis and cardiac infarction.

Description

【発明の詳細な説明】 〈産業上の利用分野〉 この発明は血清脂質改善機能を有する組成物に関する。[Detailed description of the invention] <Industrial application field> The present invention relates to a composition having a serum lipid improving function.

〈発明の背景〉 近年癌や心臓病或は脳卒中等の成人病が著しく増加しつ
つあり、数年前よりこの3つの疾患による死亡者数が3
大死因として年間死亡者総数の上位3位を占めるに至っ
ている。
<Background of the invention> In recent years, adult diseases such as cancer, heart disease, and stroke have been increasing significantly, and since several years ago, the number of deaths from these three diseases has increased by 3.
As a major cause of death, it ranks in the top three in the total number of deaths each year.

これらの疾患のうち心臓病と脳卒中は血中のコレステロ
ールや燐脂質や中性脂肪等が正常値の範囲を大きく上回
る所謂高脂血症が最大の引金になっている。即ち高脂血
症は動脈硬化の大きな原因となり、動脈硬化は心臓病や
脳卒中をはじめ細動脈に富む各臓器に重大な虚血性の障
害を引き起こす。また動脈硬化は高血圧の一因ともなり
、高血圧も心臓病や脳卒中の発症の危険度を高くする。
Among these diseases, the main trigger for heart disease and stroke is so-called hyperlipidemia, in which blood cholesterol, phospholipids, triglycerides, etc. greatly exceed the normal range. That is, hyperlipidemia is a major cause of arteriosclerosis, and arteriosclerosis causes serious ischemic disorders in various organs rich in arterioles, including heart disease and stroke. Arteriosclerosis also contributes to high blood pressure, which also increases the risk of developing heart disease and stroke.

高脂血症が増加している原因は、主として従来の魚肉や
野菜を中心とした食事から牛や豚等の畜肉を中心とした
食事への食生活の変化に起因していると考えられる。牛
肉や豚肉はコレステロール等が多く、これが血管内皮下
に浸透蓄積してアローム腫を形成し、血管内皮を押し上
げて血管内腔を狭窄する。また牛肉や豚肉にはアラキド
ン酸が多く含まれており、これが血小板の凝集粘着を強
化して血栓の過形成を促す。これらの要因により血栓症
や塞栓症、即ち心筋梗塞や脳梗塞が引き起こされる。
The cause of the increase in hyperlipidemia is thought to be mainly due to a change in dietary habits from a conventional diet centered on fish and vegetables to a diet centered on livestock meat such as beef and pork. Beef and pork contain a lot of cholesterol, etc., which penetrates and accumulates under the vascular endothelium, forming aromatic tumors, pushing up the vascular endothelium and narrowing the vascular lumen. In addition, beef and pork contain a large amount of arachidonic acid, which strengthens the aggregation of platelets and promotes the hyperplasia of blood clots. These factors cause thrombosis and embolism, that is, myocardial infarction and cerebral infarction.

〈発明が解決しようとする課題〉 従来このような高脂血症を予防或は治療するためには、
食生活の改善と運動量の増加等が必要であると云われて
いるが、これらを日常生活の中で継続して行うのは必ず
しも容易ではない。また、種々の予防剤や治療剤が知ら
れているが、効果が十分ではなくまた副作用が大きいな
どの問題があった。また薬品として服用しなければなら
ない等の問題があった。
<Problem to be solved by the invention> Conventionally, in order to prevent or treat such hyperlipidemia,
Although it is said that it is necessary to improve eating habits and increase the amount of exercise, it is not necessarily easy to continue to do these things in daily life. Furthermore, various preventive and therapeutic agents are known, but they have problems such as insufficient efficacy and large side effects. There were also problems such as the need to take it as a medicine.

そのため、もし副作用がなく食品として摂取するか或は
食品に配合して摂取できる血清脂質改善効果を示す組成
物が開発されたならば、広く健康に及ぼす影響には多大
なものが予想され、従来よりそのような組成物の開発が
望まれている。
Therefore, if a composition with a serum lipid improving effect that can be taken as food or mixed with food without side effects is developed, it would be expected to have a huge impact on a wide range of health. It is desired to develop more such compositions.

本発明はこのような要望に応えるためになされたもので
1食料品として摂取或は食料品に混合して摂取すること
が可能でしがも優れた血清脂質改善効果を示す組成物を
提供することを目的とするものである。
The present invention was made in response to such demands, and provides a composition that can be taken as a single food product or mixed with food products, and that exhibits an excellent serum lipid improving effect. The purpose is to

〈発明の概要〉 上記目的を達成するために、本発明者らは、生体内にお
ける各種不飽和脂肪酸や不飽和炭化水素の作用に着目し
、α−リノレン酸なども含めた種々の成分を対象として
、効果的な配合材料の種類と配合比率について実験研究
を重ねた結果、食料品として摂取或は食料品に混合して
摂取することが可能でしかも優れた血清脂質改善効果を
示す組成物を開発するにいたった。
<Summary of the Invention> In order to achieve the above object, the present inventors focused on the effects of various unsaturated fatty acids and unsaturated hydrocarbons in vivo, and targeted various components including α-linolenic acid. As a result of repeated experimental research on the types and ratios of effective compounding materials, we have developed a composition that can be taken as food or mixed with food, and that has an excellent serum lipid improvement effect. I ended up developing it.

即ち本発明の血清脂質改善作用を有する組成物は、スク
アレン、魚油及びビタミンEを含有することを基本的な
特徴とする。またこれらに加えて大豆レシチン、植物油
を含有するのが望ましい。
That is, the composition having a serum lipid improving effect according to the present invention is basically characterized by containing squalene, fish oil, and vitamin E. In addition to these, it is desirable to contain soybean lecithin and vegetable oil.

魚油には通常エイコサペンタエン酸及びドコサヘキサエ
ン酸が含有されているが、これらは血清脂質改善効果に
寄与するところが大きいため、エイコサペンタエン酸と
ドコサヘキサエン酸を多く含有する魚油を用いるのが望
ましい。また植物油にはリノール酸やγ−リノレン酸を
含有するものがあり、これらは同様に血清脂質改善効果
を有するからリノール酸とγ−リノレン酸を多く含有す
る植物油を用いるのが望ましい、具体的には月見草オイ
ル等がリノール酸とγ−リノレン酸を多く含有している
Fish oil usually contains eicosapentaenoic acid and docosahexaenoic acid, and since these greatly contribute to the serum lipid improving effect, it is desirable to use a fish oil containing a large amount of eicosapentaenoic acid and docosahexaenoic acid. In addition, some vegetable oils contain linoleic acid and γ-linolenic acid, and these also have the effect of improving serum lipids, so it is desirable to use vegetable oils that contain a large amount of linoleic acid and γ-linolenic acid. Evening primrose oil contains large amounts of linoleic acid and γ-linolenic acid.

上記各成分の含有比率としては、本発明者らの研究によ
れば、スクアレン:30wt%以上85wt%以下、魚
油: 5wt%以上50wt%以下。
According to research by the present inventors, the content ratios of each of the above components are squalene: 30 wt% or more and 85 wt% or less, and fish oil: 5 wt% or more and 50 wt% or less.

大豆レシチン: 5wt%以上50wt%以下、植物油
:5wt%以上50wt%以下、ビタミンE:0.1w
t%以上10 w t%以下とするのが最も血清脂質改
善効果が高かった。
Soybean lecithin: 5wt% or more and 50wt% or less, vegetable oil: 5wt% or more and 50wt% or less, vitamin E: 0.1w
The serum lipid improving effect was highest when the content was t% or more and 10 wt% or less.

また魚油はエイコサペンタエン酸を20wt%以上且つ
ドコサヘキサエン酸を10wt%以上含有するのが血清
脂質改善効果の点から望ましい。
Further, it is desirable that the fish oil contains 20 wt% or more of eicosapentaenoic acid and 10 wt% or more of docosahexaenoic acid from the viewpoint of serum lipid improving effect.

また植物油はリノール酸を50wt%以上且っγ−リノ
レン酸を7wt%以上含有するのが血清脂質改善効果の
向上の点から望ましい。更にビタミンEは総トコフェロ
ールとして60wt%以上を含有するのが望ましい。
In addition, it is desirable that the vegetable oil contains 50 wt % or more of linoleic acid and 7 wt % or more of γ-linolenic acid from the viewpoint of improving the serum lipid improving effect. Furthermore, it is desirable that vitamin E contains 60 wt% or more as total tocopherol.

上記組成物は液体食品材料としてそのままで用いること
も出来るが、サラダ油等の他の食品材料に配合して用い
てもよい。
The above composition can be used as it is as a liquid food material, but it may also be used by blending it with other food materials such as salad oil.

〈実施例〉 上記組成物につきその効果を臨床試験により確認した。<Example> The effectiveness of the above composition was confirmed through clinical trials.

その実施例を以下説明する。An example thereof will be described below.

実施例1: すでに高脂血症の診断をうけている者10名について、
つぎのような臨床試験を試みた。すなわち下記成分の本
発明に係る組成物を1回900mgずつ食品として1日
3回の食事の都度摂取させた。4か月間摂取を継続し、
1か月ごとに血中の総コレステロール、燐脂質、中性脂
肪、β−リボ蛋白、 遊離コレステロール、HDLコレ
ステロールのそれぞれの値を検査した。その結果を、1
0名の平均値で第1図に示す。
Example 1: Regarding 10 people who had already been diagnosed with hyperlipidemia,
The following clinical trials were attempted. That is, 900 mg of the composition according to the present invention having the following ingredients was ingested as food at each meal three times a day. Continued intake for 4 months,
Blood total cholesterol, phospholipid, triglyceride, β-riboprotein, free cholesterol, and HDL cholesterol values were tested every month. The result is 1
Figure 1 shows the average value for 0 people.

なお、それぞれの検音項目の正常値または基準値の範囲
は、総コレステロール:120mg以上250 m g
 / d l以下、燐脂質:150mg以上280mg
/di以下、中性脂肪: 40 m g以上170mg
/di以下、β−リポ蛋白:200mg以上550mg
/dl以下、遊離コレステロール:30mg以上60 
m g / d l以下、HDLニルステロールは男性
で40 m g以上70 m g / d1以下1女性
で45mg以上75 m g / d l以下とされて
いる。
The range of normal values or reference values for each test item is: total cholesterol: 120 mg or more, 250 mg
/ dl or less, phospholipid: 150mg or more 280mg
/di or less, neutral fat: 40 mg or more 170 mg
/di or less, β-lipoprotein: 200mg or more 550mg
/dl or less, free cholesterol: 30 mg or more 60
mg/dl or less, and HDL nylsterol is 40 mg or more and 70 mg/dl or less for men and 45 mg or more and 75 mg/dl or less for women.

(組成物) スクアレン   :  55.56wt%魚油  : 
16.67wt% 大豆レシチン  :  12.22wt%月見草オイル
  :  13.33wt%ビタミンEオイル;   
2.22wt%また各成分の構成は次の通りである。
(Composition) Squalene: 55.56wt% Fish oil:
16.67wt% soybean lecithin: 12.22wt% evening primrose oil: 13.33wt% vitamin E oil;
2.22wt% The composition of each component is as follows.

スクアレン:純度は99.9% 魚油:エイコサペンタエン酸を23.0wt%及びドコ
サヘキサエン酸を12..0wt%更にビタミンEを1
.2%含有 大豆レシチン:アセトン不溶物として60.0%月見草
オイル:リノール酸を60.0wt%、γ−リノレン酸
を7.5wt%含有 ビタミンE:総トコフェロールとして70.0%含有 第1図の臨床試験結果かられかるように本発明による組
成物によれば、摂取開始1か月後の検査の時点で既に充
分な効果がみられ、血中脂質の種類の全てについてバラ
ンスの取れた効果が得られている。しかも副作用は全く
見られなかった。
Squalene: 99.9% purity Fish oil: 23.0 wt% eicosapentaenoic acid and 12.0 wt% docosahexaenoic acid. .. 0wt% plus 1 vitamin E
.. Contains 2% Soybean lecithin: 60.0% as acetone insoluble matter Evening primrose oil: Contains 60.0wt% linoleic acid and 7.5wt% γ-linolenic acid Vitamin E: Contains 70.0% as total tocopherol Figure 1 As can be seen from the clinical test results, the composition according to the present invention already showed sufficient effects at the time of testing one month after the start of intake, and had a well-balanced effect on all types of blood lipids. It has been obtained. Moreover, no side effects were observed.

実施例2: 従来より血中脂質が高値でその進行を懸念し、本発明に
係わる組成物の試飲を希望する者28人に、実施例1と
同一の組成物を2700mg/日乃至4500mg/日
、連続6か月間投与したところ、従来から悩んでいた慢
性的な頭痛・頭重感。
Example 2: The same composition as in Example 1 was administered at 2700 mg/day to 4500 mg/day to 28 people who had conventionally high blood lipid levels and were concerned about their progression and who wished to sample the composition according to the present invention. After administering the drug for 6 consecutive months, I experienced chronic headaches and a feeling of headache that I had been suffering from for a long time.

首筋・肩の凝りなどは、摂取開始後半くは2日又は3日
で、遅くも5日程度で全て消失を見た。また副作用その
他の異状は全く見られなかった。
Stiffness in the neck and shoulders completely disappeared within the second half of the second or third day after starting the intake, and within about five days at the latest. Furthermore, no side effects or other abnormalities were observed.

実施例3: 20匹のラッテに1か月間連続して毎日8g/kgずつ
実施例1と同一の組成物を経口投与した。
Example 3: The same composition as in Example 1 was orally administered to 20 rats at 8 g/kg daily for one month continuously.

また該組成物42 g/k gを1か月間毎日20匹の
マウスに経口投与した。その後10日間状態を観察した
が死亡はOであり、全く毒性はなかった。
Further, 42 g/kg of the composition was orally administered to 20 mice every day for one month. After that, the condition was observed for 10 days, but there was no death, and there was no toxicity at all.

即ち急性毒性はLD、。が35 g / k g以上で
あることを確認した。
That is, acute toxicity is LD. It was confirmed that the weight was 35 g/kg or more.

以上の各実施例に示すように本発明の組成物は食料品と
して或は食料品に配合して摂取することができ、しかも
極めてすぐれた血清脂質改善作用を有する。
As shown in the above examples, the composition of the present invention can be ingested as a food product or mixed into a food product, and has an extremely excellent serum lipid improving effect.

〈発明の効果〉 以上説明したように本発明の組成物は、食料品として或
は他の食料品に配合して摂取することが可能であり、短
期間で血中脂質の改善効果がありしかも副作用がない。
<Effects of the Invention> As explained above, the composition of the present invention can be ingested as a food product or mixed with other food products, and has the effect of improving blood lipids in a short period of time. No side effects.

そのため血栓形成防止作用及び血栓症治療効果があり、
脳梗塞や心筋梗塞の予防及び治療に用いることが可能で
ある。
Therefore, it has antithrombotic and thrombotic treatment effects.
It can be used for the prevention and treatment of cerebral infarction and myocardial infarction.

【図面の簡単な説明】[Brief explanation of drawings]

第1図は実施例1のコレステロール等血清脂質量の変化
を示すグラフである。 特許出願人   日誠マリン工業株式会社代理人   
  弁理士 高 橋 清
FIG. 1 is a graph showing changes in the amount of serum lipids such as cholesterol in Example 1. Patent applicant Nissei Marine Industry Co., Ltd. Agent
Patent attorney Kiyoshi Takahashi

Claims (1)

【特許請求の範囲】 1)スクアレン、魚油及びビタミンEを含有する血清脂
質改善機能を有する組成物。 2)スクアレン、魚油、大豆レシチン、植物油及びビタ
ミンEを含有する血清脂質改善機能を有する組成物。 3)スクアレン、エイコサペンタエン酸とドコサヘキサ
エン酸を多く含有する魚油、大豆レシチン、リノール酸
とγ−リノレン酸を多く含有する植物油及びビタミンE
を含有する血清脂質改善機能を有する組成物。 4)スクアレン:30wt%以上85wt%以下、魚油
:5wt%以上50wt%以下、大豆レシチン:5wt
%以上50wt%以下、植物油:5wt%以上50wt
%以下、ビタミンE:0.1wt%以上10wt%以下
、を含有する血清脂質改善機能を有する組成物。 5)魚油がエイコサペンタエン酸を20wt%以上及び
ドコサヘキサエン酸を10wt%以上含有する請求項第
4項に記載の血清脂質改善機能を有する組成物。 6)植物油がリノール酸を50wt%以上及びγ−リノ
レン酸を7wt%以上含有する請求項第4項に記載の血
清脂質改善機能を有する組成物。
[Scope of Claims] 1) A composition containing squalene, fish oil, and vitamin E and having a serum lipid improving function. 2) A composition containing squalene, fish oil, soybean lecithin, vegetable oil, and vitamin E and having a serum lipid improving function. 3) Squalene, fish oil rich in eicosapentaenoic acid and docosahexaenoic acid, soybean lecithin, vegetable oil rich in linoleic acid and gamma-linolenic acid, and vitamin E.
A composition having a serum lipid improving function. 4) Squalene: 30wt% or more and 85wt% or less, Fish oil: 5wt% or more and 50wt% or less, Soybean lecithin: 5wt
% or more and 50wt% or less, vegetable oil: 5wt% or more and 50wt
% or less, and vitamin E: 0.1 wt% or more and 10 wt% or less. 5) The composition having a serum lipid improving function according to claim 4, wherein the fish oil contains 20 wt% or more of eicosapentaenoic acid and 10 wt% or more of docosahexaenoic acid. 6) The composition having a serum lipid improving function according to claim 4, wherein the vegetable oil contains 50 wt% or more of linoleic acid and 7 wt% or more of γ-linolenic acid.
JP2293763A 1990-11-01 1990-11-01 Composition having serum lipid-improving function Pending JPH04169525A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2293763A JPH04169525A (en) 1990-11-01 1990-11-01 Composition having serum lipid-improving function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2293763A JPH04169525A (en) 1990-11-01 1990-11-01 Composition having serum lipid-improving function

Publications (1)

Publication Number Publication Date
JPH04169525A true JPH04169525A (en) 1992-06-17

Family

ID=17798904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2293763A Pending JPH04169525A (en) 1990-11-01 1990-11-01 Composition having serum lipid-improving function

Country Status (1)

Country Link
JP (1) JPH04169525A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248779B1 (en) 1995-04-21 2001-06-19 Sekisui Kagaku Kogyo Kabushiki Kaisha External preparations for treating dermatoses
KR20020069539A (en) * 2001-02-26 2002-09-05 주식회사 두산 Composition for healthy brain
JP2006050910A (en) * 2004-08-10 2006-02-23 Mukogawa Gakuin Fat metabolism-improving food composition, and food containing the same
WO2005063231A3 (en) * 2003-12-31 2006-05-18 Igennus Ltd Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
WO2007057090A1 (en) * 2005-11-18 2007-05-24 Farmaleis, S.L. A combination comprising squalene, a phospholipid and an omega 3 fatty acid for the treatment of cancer
WO2008093848A1 (en) * 2007-02-02 2008-08-07 Sunstar Inc. Composition for decreasing inflammation marker comprising phosphatidylcholine
EP1710296A4 (en) * 2003-12-02 2009-11-25 Suntory Holdings Ltd Fat composition containing phospholipid and long-chain polyunsaturated fatty acid-supplying compound and food using the same

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248779B1 (en) 1995-04-21 2001-06-19 Sekisui Kagaku Kogyo Kabushiki Kaisha External preparations for treating dermatoses
US6306898B1 (en) 1995-04-21 2001-10-23 Sekisui Kaisha Kogyo Kabushiki Kaisha External preparations for the treatment of dermatoses
KR20020069539A (en) * 2001-02-26 2002-09-05 주식회사 두산 Composition for healthy brain
EP1710296A4 (en) * 2003-12-02 2009-11-25 Suntory Holdings Ltd Fat composition containing phospholipid and long-chain polyunsaturated fatty acid-supplying compound and food using the same
KR101144834B1 (en) * 2003-12-02 2012-05-11 산토리 홀딩스 가부시키가이샤 Fat composition containing phospholipid and long-chain polyunsaturated fatty acid supplying compound and food using the same
WO2005063231A3 (en) * 2003-12-31 2006-05-18 Igennus Ltd Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
JP2006050910A (en) * 2004-08-10 2006-02-23 Mukogawa Gakuin Fat metabolism-improving food composition, and food containing the same
WO2007057090A1 (en) * 2005-11-18 2007-05-24 Farmaleis, S.L. A combination comprising squalene, a phospholipid and an omega 3 fatty acid for the treatment of cancer
WO2008093848A1 (en) * 2007-02-02 2008-08-07 Sunstar Inc. Composition for decreasing inflammation marker comprising phosphatidylcholine
JPWO2008093848A1 (en) * 2007-02-02 2010-05-20 サンスター株式会社 Inflammatory marker reducing composition containing phosphatidylcholine

Similar Documents

Publication Publication Date Title
Gogus et al. n‐3 Omega fatty acids: a review of current knowledge
McLennan et al. Dietary canola oil modifies myocardial fatty acids and inhibits cardiac arrhythmias in rats
JP4870430B2 (en) Composition for prevention and treatment of varicose veins
Bronsgeest-Schoute et al. The effect of various intakes of ω3 fatty acids on the blood lipid composition in healthy human subjects
Connor et al. Are fish oils beneficial in the prevention and treatment of coronary artery disease?
Fife The Coconut Oil Miracle: Use Nature's Elixir to Lose Weight, Beautify Skin and Hair, Prevent Heart Disease, Cancer, and Diabetes, Strengthen the Immune System
KR0126286B1 (en) Fatty acid composition
US20080113046A1 (en) Use of Omega-3 Fatty Acid(s) for Treating Hypercholesterolemia Caused by Anti-Retroviral Treatment of Hiv-Infected Patients
JP2004507498A (en) Composition for treating hypertriglyceridemia and method for treating the same
Asif Chemical characteristics and nutritional potentials of unsaturated fatty acids
JPH10504016A (en) Enteric formulations for the treatment of inflammation and infections comprising saponins, preferably in combination with other compounds
DE3213744A1 (en) PHARMACEUTICAL AGENT
JPH04290822A (en) Allergy preventing medicine and food
JPH04169525A (en) Composition having serum lipid-improving function
Sanders Influence of fish-oil supplements on man
US20170216237A1 (en) Monounsaturated fatty acid compositions and use for treating atherosclerosis
Martin The combined role of atheroma, cholesterol, platelets, the endothelium and fibrin in heart attacks and strokes
JPH07255417A (en) Functional health food
JPS62224258A (en) Nourishing food
GB2238476A (en) Therapeutic aquatic animal and garlic products
Guilliams Fatty Acids: Essential… Therapeutic
DE10056351A1 (en) Pharmaceutical preparation containing omega-3 fatty acids and other active substances e.g. an antiinflammatory, cyclooxygenase II inhibitor, 5-lipoxygenase inhibitor or platelet aggregation inhibitor
JPH04169524A (en) Composition having serum lipid-improving activity
Ristić-Medić et al. Soybeans, Flaxseeds, and Fish Oil in the Treatment of Renal Disease
JP2000239168A (en) Cerebral apoplexy-preventing agent and composition obtained by blending the same